Atyr PHARMA (NASDAQ:ATYR) Rating Increased to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Atyr PHARMA (NASDAQ:ATYR) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

ATYR has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partners started coverage on Atyr PHARMA in a research note on Tuesday. They set an “outperform” rating and a $16.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $3.79 on Tuesday. The stock has a market capitalization of $318.13 million, a PE ratio of -4.03 and a beta of 1.10. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.22. The firm has a fifty day simple moving average of $3.55 and a 200 day simple moving average of $2.83. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Institutional Trading of Atyr PHARMA

Several institutional investors and hedge funds have recently modified their holdings of the business. Alpine Global Management LLC bought a new position in Atyr PHARMA in the fourth quarter valued at about $63,000. Woodline Partners LP acquired a new stake in Atyr PHARMA during the 4th quarter worth about $6,092,000. Squarepoint Ops LLC bought a new stake in Atyr PHARMA in the fourth quarter worth approximately $96,000. Two Sigma Advisers LP acquired a new position in shares of Atyr PHARMA during the 4th quarter valued at $44,000. Finally, Two Sigma Investments LP acquired a new position in shares of Atyr PHARMA during the fourth quarter valued at about $78,000. 61.72% of the stock is currently owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.